Previous 10 | Next 10 |
2024-07-14 08:00:00 ET Earnings season kicks into high gear in mid-July, featuring a wave of releases from some of the world's most prominent companies. The docket includes major banks, pharmaceutical firms and airlines, as well as tech and telecom giants.... Read the full article on ...
2024-07-12 17:09:10 ET More on MorphoSys MorphoSys: Novartis Deal Is All But Done MorphoSys: Hold Rating Until The Novartis Deal Closes Novartis intends to implement merger squeeze-out of MorphoSys minority shareholders MorphoSys gains after Novartis disclose...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...
2024-07-12 11:40:22 ET Summary Lantheus, known for its radiopharmaceutical Pylarify, experienced a significant boost following positive CMS payment updates. Pylarify's increased revenue contributed significantly to Q1 earnings, reflecting a robust market demand for this leading pr...
2024-07-12 07:00:00 ET Summary Stocks keep setting record highs, with valuations becoming steadily more challenging. But even at record highs, there are plenty of blue-chip bargains to buy. Free cash flow yield is a gold standard of valuation. It combines yield and quality and, if...
2024-07-11 11:42:26 ET Summary Biogen Inc.'s shares have risen 20% since its first quarter earnings report, with hopes for new product launches to boost revenue. However, its Alzheimer's medicine, Leqembi, now faces new competition from Eli Lilly, and its MS franchise has various ...
2024-07-09 13:22:33 ET More on Global X Artificial Intelligence & Technology ETF: AIQ: No Real AI Alpha With Heavy Tech Concentration Facing Slowing Growth AIQ: AI Commercialization Will Propel This ETF Higher, Despite Reaching ATH AIQ: Has Generative AI Peaked? ...
2024-07-09 09:00:37 ET Summary This article updates one I wrote in August 2022, which was based on a template article by David Van Knapp published in June 2020. I use an adapted quality scoring system to assess the quality of dividend growth stocks. The system employs six qual...
2024-07-09 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:34:52 ET Summary Novartis is close to completing its acquisition of MorphoSys, a deal valued at EUR 2.7 billion, initially agreed upon in February. Despite concerns over safety issues with MorphoSys’ lead drug, pelabresib, the likelihood of these affecting the...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...